{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:34:44Z","timestamp":1760146484896,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project of Medical and Health Science and Technology Innovation, Chinese Academy of Medical Sciences","award":["2021-I2M-1-043"],"award-info":[{"award-number":["2021-I2M-1-043"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: The serotype 2 oral poliovirus vaccine (OPV2) can revert to regain wild-type neurovirulence and spread, causing the emergence of vaccine-derived poliovirus (VDPV2) and immunodeficiency-related vaccine-derived polioviruses (iVDPVs). In the United States, testing carried out by the CDC of type II iVDPV (iVDPV2) with human immune serum from the vaccine has shown that the presence of the virus poses a threat to eradication efforts. Methods: We analyzed the major neutralization sites of VP1, VP2, and VP3 of the iVDPV using bioinformatics techniques and homology modeling (SWISS-MODEL). The three amino acid residues 679, 680, and 141 of the P1 region changed, which had an impact on the spatial conformation of the viral-neutralizing site. We tested polio-vaccinated human sera and rabbit anti-Sabin II polyantibodies against a panel of iVDPV pseudoviruses. Results: The results demonstrated that the serum\u2019s capacity to neutralize mutant pseudoviruses diminished when amino acid substitutions were introduced into the P1 encapsidated protein, particularly when 141 and 679 were mutated together. This study emphasizes the significance of continually monitoring individuals who are known to be immunocompromised and maintaining high vaccination rates in OPV-using communities.<\/jats:p>","DOI":"10.3390\/v16111761","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T05:21:59Z","timestamp":1731388919000},"page":"1761","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient"],"prefix":"10.3390","volume":"16","author":[{"given":"Yanan","family":"Wu","sequence":"first","affiliation":[{"name":"Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runfang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"},{"name":"Institute of Medical Biology, Kunming Medical University, Kunming 650500, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbo","family":"Yuan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Industrial Transformation, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohu","family":"Dai","sequence":"additional","affiliation":[{"name":"Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyun","family":"Chuan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Production Department, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilan","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoyang","family":"Liao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Li","sequence":"additional","affiliation":[{"name":"Production Department, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Industrial Transformation, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1191\/1740774504cn010xx","article-title":"The Salk Polio Vaccine Trial of 1954: Risks, randomization and public involvement in research","volume":"1","author":"Dawson","year":"2004","journal-title":"Clin. Trials"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0264-410X(02)00399-7","article-title":"The assessment of OPV vaccines by the monkey neurovirulence test: Why and how to qualify the experts in histology of central nervous system","volume":"21","author":"Poirier","year":"2002","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.vaccine.2020.02.035","article-title":"Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients","volume":"38","author":"McDonald","year":"2020","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11357-022-00672-7","article-title":"Poliomyelitis is a current challenge: Long-term sequelae and circulating vaccine-derived poliovirus","volume":"45","author":"Quarleri","year":"2023","journal-title":"Geroscience"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Anis, E., Kopel, E., Singer, S.R., Kaliner, E., Moerman, L., Moran-Gilad, J., Sofer, D., Manor, Y., Shulman, L.M., and Mendelson, E. (2013). Insidious Reintroduction of Wild Poliovirus into Israel, 2013. Eurosurveillance, 18.","DOI":"10.2807\/1560-7917.ES2013.18.38.20586"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-3292-4_1","article-title":"An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication","volume":"1387","author":"Minor","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMp1104329","article-title":"The polio endgame","volume":"364","author":"Aylward","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/infdis\/jiq148","article-title":"Eradication of poliovirus: Fighting fire with fire","volume":"203","author":"Nathanson","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/2249-4863.104936","article-title":"Polio eradication: Current status and challenges","volume":"1","author":"Bhaumik","year":"2012","journal-title":"J. Family Med. Prim. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/cid\/cix110","article-title":"Immune Serum from Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses","volume":"64","author":"Sun","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/CVI.05225-11","article-title":"Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum","volume":"18","author":"Arita","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1099\/vir.0.82172-0","article-title":"Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon","volume":"87","author":"Arita","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15H.4.1","DOI":"10.1002\/cpmc.47","article-title":"Poliovirus Replicon RNA Generation, Transfection, Packaging, and Quantitation of Replication","volume":"48","author":"Viktorova","year":"2018","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Arita, M., and Iwai-Itamochi, M. (2019). Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-48534-1"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhang, H., An, D., Liu, W., Mao, Q., Jin, J., Xu, L., Sun, S., Jiang, L., Li, X., and Shao, J. (2014). Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay. PLoS ONE., 9.","DOI":"10.1371\/journal.pone.0100545"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jmv.24909","article-title":"A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus","volume":"89","author":"Liu","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/bioinformatics\/bti770","article-title":"The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling","volume":"22","author":"Arnold","year":"2006","journal-title":"Bioinformatics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"D230","DOI":"10.1093\/nar\/gkh008","article-title":"The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models","volume":"32","author":"Kopp","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/bmb.20966","article-title":"Using the PyMOL Application to Reinforce Visual Understanding of Protein Structure","volume":"44","author":"Rigsby","year":"2016","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/viro.1993.1044","article-title":"Antigenic sites on type 2 poliovirus","volume":"192","author":"Patel","year":"1993","journal-title":"Virology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W and Clustal X version 2.0","volume":"23","author":"Larkin","year":"2007","journal-title":"Bioinformatics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: Multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01731581","article-title":"A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences","volume":"16","author":"Kimura","year":"1980","journal-title":"J. Mol. Evol."},{"key":"ref_24","first-page":"124","article-title":"Antigenic structure of picornaviruses","volume":"161","author":"Minor","year":"1990","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.15585\/mmwr.mm7214a3","article-title":"Update on Vaccine-Derived Poliovirus Outbreaks\u2014Worldwide, January 2021\u2013December 2022","volume":"72","author":"Bigouette","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.15585\/mmwr.mm7341a1","article-title":"Update on Vaccine-Derived Poliovirus Outbreaks\u2014Worldwide, January 2023\u2013June 2024","volume":"73","author":"Greene","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.vaccine.2018.02.059","article-title":"New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data","volume":"36","author":"Shaghaghi","year":"2018","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Howard, W., Moonsamy, S., Seakamela, L., Jallow, S., Modiko, F., du Plessis, H., Sibiya, R., Kamupira, M., Maseti, E., and Suchard, M. (2021). Sensitivity of the acute flaccid paralysis surveillance system for poliovirus in South Africa, 2016\u20132019. J. Med. Microbiol., 70.","DOI":"10.1099\/jmm.0.001441"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4049\/jimmunol.1202014","article-title":"Conformational Shift of a Major Poliovirus Antigen Confirmed by Immuno-Cryogenic Electron Microscopy","volume":"191","author":"Lin","year":"2013","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1099\/vir.0.18708-0","article-title":"Characterization of a recombinant type 3\/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1","volume":"84","author":"Blomqvist","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1128\/jvi.62.5.1781-1794.1988","article-title":"Three-dimensional structure of poliovirus serotype 1 neutralizing determinants","volume":"62","author":"Page","year":"1988","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.virol.2017.07.032","article-title":"Polioviruses that bind a chimeric Pvr\u2013nectin-2 protein identify capsid residues involved in receptor interaction","volume":"510","author":"Lin","year":"2017","journal-title":"Virology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1761\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:30:34Z","timestamp":1760113834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["v16111761"],"URL":"https:\/\/doi.org\/10.3390\/v16111761","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}